Subcutaneous panniculitis-like T-cell lymphoma is a rare form of cutaneous lymphoma that often presents a diagnostic and therapeutic challenge for clinicians. Recent research using the Surveillance, Epidemiology, and End Results (SEER) database has shed light on its clinical behavior and long-term prognosis. This study analyzed 205 patients diagnosed between 2000 and 2021. It highlighted that overall survival at five years was approximately 66.4%. Notably, patients diagnosed after 2008 showed significantly improved outcomes. This shift likely reflects better clinical differentiation from more aggressive subtypes.

Several factors influence the clinical course of this inflammatory lymphoma. For instance, age serves as a critical independent predictor of patient outcomes. Specifically, patients older than 50 years face a higher hazard risk compared to younger individuals. Conversely, Asian or Pacific Islander ethnicity was associated with more favorable survival rates in this cohort. These findings help clinicians stratify risks more effectively when managing this rare and often misunderstood condition.

Treatment Strategies for Subcutaneous Panniculitis-Like T-Cell Lymphoma

Regarding therapeutic options, the study revealed surprising insights into the efficacy of various modalities. Radiotherapy alone emerged as a highly effective option for patients presenting with localized or single skin lesions. Interestingly, the data showed no significant prognostic benefit for chemotherapy or combined radiochemotherapy over no systemic treatment in many cases. Therefore, the findings suggest that immunomodulatory agents might be preferable to traditional cytotoxic therapy as an initial approach. This is particularly relevant given the inflammatory nature of the disease.

Finally, the researchers noted that the traditional Ann Arbor staging system is not suitable for this specific lymphoma. Since the disease predominantly involves the subcutaneous tissue without lymph node involvement, other staging models may better reflect patient outcomes. Clinicians should prioritize early identification and personalized treatment plans to improve long-term survival for those affected.

What are the independent predictors of survival in SPTCL?

According to the SEER database analysis, independent predictors of favorable survival include being of Asian or Pacific Islander descent and being diagnosed after 2008. In contrast, age over 50 years and diagnosis before 2008 are associated with a poorer prognosis.

Is chemotherapy always necessary for SPTCL?

No, the study found that chemotherapy or radiochemotherapy did not significantly improve prognosis compared to no chemotherapy in some cohorts. For localized lesions, radiotherapy alone is often sufficient and carries a significantly lower hazard risk.

Why is Ann Arbor staging considered unsuitable?

The Ann Arbor system is designed primarily for nodal lymphomas. Since Subcutaneous panniculitis-like T-cell lymphoma affects subcutaneous fat and rarely involves lymph nodes, this staging method fails to accurately predict the disease course or guide treatment effectively.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice or a professional relationship. Always seek the advice of a qualified healthcare provider for any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

1. Zhang L et al. Clinical characteristics, treatment options, and prognosis of subcutaneous panniculitis-like T-cell lymphoma from the SEER database. Hematology. 2026 Dec 31. doi: 10.1080/16078454.2026.2648344. PMID: 41876379.

2. StatPearls. Subcutaneous Panniculitis-Like T-cell Lymphoma. Treasure Island (FL): StatPearls Publishing; 2024.

3. Willemze R et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768-3785.